IceCure Medical (NASDAQ:ICCM) Releases Earnings Results, Misses Estimates By $0.01 EPS

IceCure Medical (NASDAQ:ICCM - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01), Zacks reports. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%.

IceCure Medical Stock Up 6.8 %

NASDAQ ICCM traded up $0.08 on Monday, hitting $1.19. 210,528 shares of the company were exchanged, compared to its average volume of 520,720. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The company has a market cap of $65.77 million, a PE ratio of -4.09 and a beta of 0.37. The stock has a fifty day moving average of $1.32 and a 200-day moving average of $0.99.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $2.50 price target on shares of IceCure Medical in a report on Friday.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.